Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BeOne

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BeOne Study ID

BGB-A317-Sitravatinib-301

ClinicalTrials.gov ID

NCT04921358

EudraCT Number

2022-001779-15

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

No Study Documents